Home › Compare › UPNRF vs ABBV
UPNRF yields 2.58% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, UPNRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of UPNRF + ABBV for your $10,000?
Uponor Oyj provides plumbing, indoor climate, and infrastructure solutions in Europe and North America. The company operates through three segments: Building Solutions Europe, Building Solutions North America, and Uponor Infra. It offers drinking water delivery systems, including plastic plumbing pipe systems, multi-layer composite pipe systems for residential buildings, commercial and public buildings; underfloor heating and cooling, comprising floor integrated underfloor heating systems, water based floor heating, and electric underfloor heating for new buildings and renovation projects; wall heating and cooling systems radiant heating and cooling via the wall, for wet and dry plaster installation systems in new buildings and renovation projects. The company also provides ceiling heating and cooling for offices, sales areas, industrial buildings, and sports halls; room and supply temperature controls; mainfolds vario distribution units and cabinets, pre-assembled, and modern approach in residential buildings; flexible ecoflex pre-insulated pipes; prefabricated modules for plumbing and heating; heating and cooling products for projects; and radiator connections. Uponor Oyj was founded in 1918 and is based in Vantaa, Finland.
Full UPNRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.